VidsHive News Recombinant Zoster Vaccine Linked to Lower Cardiovascular Risk in Adults With HIV

WASHINGTON, DC — Findings presented at IDWeek 2026 indicate that the recombinant zoster vaccination may help decrease incident heart failure risk among adults living with HIV. The research highlights a potential protective benefit against cardiovascular complications that can be elevated by herpes zoster.

The annual conference, held from October 21 to 24 in Washington, DC, served as the platform for the presentation. Because HIV infection is linked to a heightened risk of cardiovascular events driven by chronic immune activation, researchers sought to investigate how vaccination might influence these outcomes.

To perform the evaluation, investigators utilized data from TriNetX to design complementary, retrospective, 1:1 propensity-score matched cohort analyses. The study focused specifically on adults living with HIV who were receiving antiretroviral therapy.

The European AIDS Treatment Group (EATG) highlighted the research outcomes as part of its ongoing dissemination of important updates concerning HIV and co-infections for affected communities, healthcare workers, and advocates.